A peptide derivative with dual GLP-1R and GIPR targeting agonist activity, its preparation method and uses
By introducing specific amino acid modifications and branched structures into peptide derivatives with dual GLP-1R and GIPR targeting agonists, the problems of instability and insufficient activity of peptide drugs in vivo in existing technologies have been solved, achieving long-lasting effects and strong drug activity, making it suitable for the treatment of diabetes, weight loss, cardiovascular diseases combined with diabetes, NASH, and neurodegenerative diseases.
Patent Information
- Application Number
- CN202280035107.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2021-06-01
- Filing Date
- 2022-05-31
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2042-05-31
AI Technical Summary
Existing GLP-1 and GIP are unstable in vivo and are easily degraded by dipeptidyl peptidase-IV. Furthermore, peptide drugs with dual targeting agonist effects of GLP-1R and GIPR have problems such as short efficacy half-life and insufficient activity in the treatment of diabetes, weight loss, cardiovascular diabetes, NASH, and neurodegenerative diseases.
A peptide derivative with dual targeting agonist effects of GLP-1R and GIPR was designed. By introducing specific amino acid modifications and branched structures into the main chain, and using solid-phase or liquid-phase synthesis techniques, peptide derivatives with long-lasting effects and strong drug activity were prepared, including stereoisomers and enantiomers.
It achieves long-lasting efficacy of peptide derivatives in vivo, significantly prolongs half-life, and enhances drug activity, especially in the treatment of diabetes, weight loss, cardiovascular disease combined with diabetes, NASH, and neurodegenerative diseases. Some of its activities are stronger than those of the control drug Tirzepatide.
Smart Images

Figure CN117440964B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of pharmaceutical technology, and in particular relates to a polypeptide derivative with dual targeting agonist effects on GLP-1R and GIPR, its preparation method and uses. Background Technology
[0002] Glucose-dependent insulinotropic polypeptide (GIP) is a 42-amino acid polypeptide secreted primarily by K cells in the proximal small intestine and was the first incretin discovered. Early studies showed that acute infusion of GIP in patients with type 2 diabetes mellitus (T2DM) elicited a diminished insulinotropic effect, limiting its potential as a drug development target. However, recent studies have found that the insulinotropic effect of GIP can be restored in T2DM patients after treatment with hypoglycemic agents to improve glycemic control. Furthermore, GIP acts on bone and adipose tissue, inhibiting bone resorption and promoting lipid synthesis in adipocytes, thereby affecting lipid metabolism and fat distribution, with effects independent of insulin action. GIP may also reduce food intake and weight loss by activating GIPR+ neurons in the hypothalamus. GIP treatment in mice improved learning and memory abilities, increased levels of brain growth factor (which protects neuronal function), reduced levels of Alzheimer's-related amyloid protein, decreased chronic inflammation and oxidative stress, and slowed neuronal apoptosis.
[0003] Glucagon-like peptide-1 (GLP-1) is a peptide hormone secreted by L cells in the human intestine. It promotes insulin secretion and inhibits glucagon secretion, thus lowering blood glucose levels and is used in the treatment of type 2 diabetes. GLP-1 exerts its physiological effects by binding to its specific receptor, GLP-1R. GLP-1R is widely distributed in multiple organs and tissues throughout the body. Evidence-based medicine also confirms that GLP-1R agonism (GLP-1RA), in addition to treating diabetes and obesity, has protective effects on the cardiovascular system, kidneys, and central nervous system. GLP-1R is widely distributed and can work with other receptors to regulate the metabolism of key target tissues.
[0004] However, natural GLP-1 and GIP are unstable in vivo and are easily degraded rapidly by dipeptidyl peptidase-IV (DPP-IV).
[0005] Eli Lilly's Tirzepatide (LY3298176), a novel drug with dual GLP-1R and GIPR agonist activity, is undergoing Phase III clinical trials for various indications. On May 14, 2022, the FDA approved Eli Lilly's Mounjaro (tirzepatide) for marketing, for use in combination with diet and exercise to improve glycemic control in adults with type 2 diabetes. Other dual-target peptide drugs are also under investigation, such as CN105849122A, CN104470948A, and CN105209485A.
[0006] Existing research has found that the optimal combination of GLP-1R and GIPR dual-targeting agonist activities is key to these drugs, with different combinations producing varying pharmacological effects and adverse reactions. Furthermore, different branching modifications can alter the dual-targeting agonist activity and half-life of these drugs. The field remains eager to explore the potential therapeutic applications of peptides with dual-targeting GLP-1R and GIPR agonist activities in treating diabetes, weight loss, cardiovascular diseases combined with diabetes, NASH, and neurodegenerative diseases such as AD and PD. Summary of the Invention
[0007] The purpose of this invention is to discover, through in-depth research and creative work, a polypeptide derivative or its salt with dual targeting agonist effects of GLP-1R and GIPR, as well as the corresponding pharmaceutical composition, whose in vivo long-term efficacy far exceeds that of similar polypeptide compounds. At the same time, it has significantly stronger drug activity and better clinical value in certain aspects at effective doses, making it of great potential in the treatment of diabetes, weight loss, cardiovascular diseases combined with diabetes, metabolic syndrome, NASH, and neurodegenerative diseases such as AD and PD.
[0008] This invention provides a polypeptide derivative or salt thereof that has dual targeting agonistic effects on GLP-1R and GIPR, wherein the polypeptide derivative has the effect shown in formula (I), and Xaa in the main chain 20 It is Lys and its side chain ε-amino is connected to the branch chain X1 in formula (II) in the form of an amide bond;
[0009] Tyr-Aib-Asp-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Xaa 13 -Leu-Asp-Lys-Ile-Ala-Gln-Xaa 20-Glu-Phe-Val-Gln-Trp-Leu-Leu-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
[0010]
[0011] Aib is aminoisobutyric acid, which is linked to the preceding and following amino acids by amide bonds (peptide bonds);
[0012] Xaa 13 For Aib, Tyr, or Ala;
[0013] Additionally, in formula (II), n is 16 or 18; X1 and X2 are simultaneously... Or X2 is Meanwhile, X1 is
[0014] In one embodiment of the present invention, in the polypeptide derivative, n is 16 in formula (II).
[0015] In one embodiment of the present invention, in the polypeptide derivative, n is 18 in formula (II).
[0016] In one embodiment of the present invention, in the polypeptide derivative, X1 and X2 in formula (II) are simultaneously...
[0017] In one embodiment of the present invention, in the polypeptide derivative, X2 in formula (II) is... Meanwhile, X1 is
[0018] In one embodiment of the present invention, the polypeptide derivative is of the following formula (1):
[0019]
[0020] In one embodiment of the present invention, the polypeptide derivative is of the following formula (2).
[0021]
[0022] In one embodiment of the present invention, the polypeptide derivative is of the following formula (3).
[0023]
[0024] In one embodiment of the present invention, the polypeptide derivative is of the following formula (4).
[0025]
[0026] In one embodiment of the present invention, the polypeptide derivative is of the following formula (5).
[0027]
[0028] In one embodiment of the present invention, the polypeptide derivative is of the following formula (6).
[0029]
[0030] In one embodiment of the present invention, the polypeptide derivative is of the following formula (7).
[0031]
[0032] In one embodiment of the present invention, the polypeptide derivative is of the following formula (8).
[0033]
[0034] In one embodiment of the present invention, the polypeptide derivative is of the following formula (9).
[0035]
[0036] In one embodiment of the present invention, the polypeptide derivative is of the following formula (10).
[0037]
[0038] In one embodiment of the present invention, the glutamine in the branched (II) formula is (L)-configuration.
[0039] The compounds of this invention can exist in specific geometric or stereoisomeric forms. This invention envisions all such compounds, including cis and trans isomers, (-)- and (+)- enantiomers, (R)- and (S)- enantiomers, diastereomers, (D)- isomers, (L)- isomers, and racemic mixtures thereof, as well as other mixtures, such as mixtures enriched with enantiomers or diastereomers, all of which are within the scope of this invention. All such isomers and mixtures thereof are included within the scope of this invention. In embodiments of this invention, as a preferred embodiment, the amino acid in the polypeptide derivative is preferably an L-type amino acid.
[0040] Unless otherwise specified, all natural amino acids mentioned in this article are internationally recognized single-letter or three-letter abbreviations, such as S or Ser for serine, and P or Pro for proline.
[0041] On the other hand, the present invention provides a method for preparing the above-mentioned polypeptide derivative, the method comprising the following step A:
[0042] 1) Synthesis of branched fragments using solid-phase or liquid-phase methods;
[0043] 2) Solid-phase synthesis of peptide chains;
[0044] 3) Couple branched fragments to peptide resin;
[0045] 4) The protecting groups and resin attachment are removed by cleavage to obtain the polypeptide derivative.
[0046] This invention provides another method for preparing the above-mentioned polypeptide derivative, the method comprising the following step B:
[0047] 1) Solid-phase synthesis of peptide chains;
[0048] 2) Solid-phase method to sequentially couple each branched module to peptide resin;
[0049] 3) The protecting groups and resin attachment are removed by cleavage to obtain the polypeptide derivative.
[0050] In some embodiments, step A of the specific preparation process is described as follows:
[0051] 1) Synthesis of branched fragments using solid-phase or liquid-phase methods;
[0052] In some embodiments, the method for synthesizing the branched fragments is as follows:
[0053] Fmoc-AEEA-OH (2-(2-(fluorenylmethoxycarbonyl-2-aminoethoxy)ethoxy)acetic acid was condensed and coupled to 2-CTC resin; Fmoc protection was removed by Pip (piperidine) / DMF (N,N-dimethylformamide) solution or other alkaline solutions; a second Fmoc-AEEA-OH was condensed and coupled to the resin; Fmoc protection was removed by Pip (piperidine) / DMF (N,N-dimethylformamide) solution or other alkaline solutions; Fmoc-Glu-OtBu was condensed and coupled to the resin; octadecanoic acid with a single protection of the tBu group was coupled to the resin; the fragment was excised using a 1% TFA (trifluoroacetic acid) DCM solution to expose the carboxyl group that needs to bind to the peptide chain.
[0054] In some embodiments, the method for synthesizing the branched fragments is as follows:
[0055] X1 is X2 is Xaa 20 When attaching a side chain to K,
[0056] Will and Condensation coupling is performed under weak organic base conditions, and TFA removes Boc protection; Fmoc-Glu-OtBu is condensed and coupled with the product from the previous step, and Fmoc protection is removed by Pip solution or other alkaline solutions; the octadecanoic acid with the tBu group is condensed and coupled to the amino position of Glu from the previous step; finally, benzyl ester is removed by hydrogen hydrolysis under palladium on carbon catalysis, exposing the carboxyl group that needs to bind to the peptide chain.
[0057] 2) Solid-phase synthesis of peptide chains;
[0058] In some embodiments, the synthesis main chain scheme is as follows:
[0059] According to the amino acid sequence of the molecular structure of this invention, Fmoc-protected amino acids are sequentially and in reverse order coupled to a solid-phase synthetic resin. Fmoc is protected with Pip solution or other alkaline solution, and the process is repeated until all amino acids in the peptide backbone are complete. The Lys of the side chain fragment to be joined is protected with Alloc (optionally, using raw material Fmoc-Lys(Alloc)-OH) or Dde (optionally, using raw material Fmoc-Lys(Dde)-OH). The terminal serine amide of the molecular structure of this invention is constructed using resins such as RinkAmide-AM resin, Rink Amide-MBHA resin, Sieber resin, PAM resin, and Rink Amide resin that can construct amide-type amino acids.
[0060] 3) Couple branched fragments to peptide resin;
[0061] In some embodiments, the coupling scheme between the branched chain and the peptide chain is as follows:
[0062] Depeptide-free resin Lys side chain protection, such as Xaa 20 When the side-chain protecting group is Alloc, it is protected by removing Alloc using tetra(triphenylphosphine)palladium and PhSiH3; such as Xaa 20 When the side chain protecting group is Dde, Dde protection is removed using hydrazine hydrate; the branched fragment is coupled to peptide resin; and the first amino acid Fmoc is removed using Pip solution or other alkaline solutions.
[0063] 4) Pyrolysis to remove protecting groups and resin attachment
[0064] The protecting groups and resin attachment were removed by cleavage to obtain crude dual-target peptide derivatives.
[0065] In some embodiments, the pyrolysis scheme is as follows:
[0066] Prepare a TFA lysis buffer according to a certain ratio, add the fully protected peptide resin to the lysis buffer, cleave the peptide from the resin and remove the side chains. Remove TFA by vacuum rotary evaporation, add ether or alkane solvent to the concentrate to precipitate a white solid, which is the target product.
[0067] Optionally, it further includes:
[0068] 5) Chromatographic purification: Perform multi-step reversed-phase chromatography or ion chromatography purification, and finally convert the salt into a salt solution or free solution of a certain acid; and 6) Lyophilization.
[0069] In some embodiments, the synthesis scheme of the main chain in step B is the same as that in step A, and the first amino acid Tyr is protected at the amino terminus by Boc.
[0070] In some embodiments, the solid-phase method in step B, which sequentially couples each branched module to the peptide resin, is as follows:
[0071] This step employs a solid-phase peptide synthesis method, where the peptide backbone is sequentially and in reverse order of the branched module structure according to the present invention. First, Xaa is removed. 20 Side chain protection connects X1 to Xaa 20 X2 is linked to X1, the glutamic acid side chain is linked to X2, and finally octadecane (or eicosane) diacid monotert-butyl ester is linked to complete the loading and synthesis of the entire side chain.
[0072] For example, X1 and X2 are Structure, Xaa 20 When attaching a side chain to K,
[0073] The main peptide chain Xaa was removed using tetra(triphenylphosphine)palladium and PhSiH3. 20 Alloc protection of (Lys) or Dde protection removed by hydrazine hydrate; activate the carboxylic acid of Fmoc-AEEA-OH(X1) with a condensation reagent, condense and couple it to the peptide chain, and remove Fmoc protection in Pip solution or other alkaline solutions; activate the carboxylic acid of Fmoc-AEEA-OH(X2) with a condensation reagent, condense and couple it to X1, and remove Fmoc protection of the first amino acid in Pip solution or other alkaline solutions; activate the carboxylic acid of Fmoc-Glu-OtBu with a condensation reagent, condense and couple it to X2, and remove Fmoc protection in Pip solution or other alkaline solutions; condense and couple the octadecane (or eicosane) diacid with the tBu group to the α-amino position of Glu; thus completing the loading and synthesis of the entire branch chain.
[0074] If X1 is X2 is Xaa 20 When attaching a side chain to K,
[0075] Alloc protection of the main peptide chain X2 (Lys) was removed using tetra(triphenylphosphine)palladium and PhSiH3, or Dde protection was removed using hydrazine hydrate; 3,6-dioxa-octanoic acid (X1) was pre-activated with a condensation reagent and then coupled and loaded with the main peptide chain; then, 3,6-dioxa-1,8-octanediamine (X2) with Fmoc monoprotection was added for condensation coupling; Fmoc protection of X2 was removed with Pip / DMF solution or other alkaline solution; Fmoc-Glu-OtBu was pre-activated with a condensation reagent and then coupled and loaded; Fmoc protection was removed with Pip / DMF solution or other alkaline solution; octadecane (or eicosane) dicofol with tBu monoprotection was condensed and coupled to the α-amino position of Glu; thus, the loading and synthesis of the entire branch chain were completed.
[0076] The condensation coupling mentioned in the text refers to the condensation coupling reaction between carboxylic acids and amino groups. Depending on the specific circumstances (such as solid-phase polypeptide synthesis), condensing agents used in organic synthesis, such as DCC / HOBt, DIC / Cl-HOBt, TBTU / DIEA, HBTU / DIEA, PyBOP / DIEA, EDC / HOBt, HATU / DIEA, T3P / DIEA, and DEPBT / TEA, can be used.
[0077] The meanings of some abbreviations in the text are explained below.
[0078] 2-CTC resin:
[0079] Sieber resin:
[0080] Rink Amide-AM resin:
[0081] Fmoc: fluorenemethyloxycarbonyl
[0082] EDC: 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide
[0083] DIC: N,N'-Diisopropylcarbodiimide
[0084] HOBt: 1-Hydroxybenzotriazole
[0085] DCC: N,N'-Dicyclopropylcarbodiimide
[0086] Cl-HOBt: 6-Chloro-1-hydroxybenzotriazole
[0087] HBTU: O-benzotriazole-N,N,N',N'-tetramethylurea hexafluorophosphate
[0088] TBTU: O-benzotriazole-N,N,N',N'-tetramethylurea tetrafluoroborate
[0089] PyBop: Benzotriazol-1-yl-oxytripyrrolidinyl hexafluorophosphate
[0090] HATU: 2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate
[0091] TIS: Triisopropylsilane
[0092] DIEA: Diisopropylethylamine
[0093] Pip: Piperidine (Hexahydropyridine)
[0094] OtBu: tert-butyl ester
[0095] DCM: Dichloromethane
[0096] MTBE: Methyl tert-butyl ether
[0097] Et2O: Diethyl ether
[0098] NMP: N-methylpyrrolidone
[0099] Bzl: Benzyl
[0100] TEA: Triethylamine
[0101] DEPBT: 3-(diethoxyphosphoryloxy)-1,2,3-benzotriazine-4-one
[0102] Dde: 1-(4,4-dimethyl-2,6-dioxocyclohexylene)ethyl
[0103] T3P: 1-Propylphosphoanhydride
[0104] Alloc: allyloxycarbonyl
[0105] tBu: tert-butyl
[0106] Pd[P(C6H5)3]4: Tetra(triphenylphosphine)palladium
[0107] PhSiH3: Phenylsilane
[0108] Thirdly, the present invention discloses a pharmaceutical composition comprising the compound described herein or a pharmaceutically acceptable salt thereof as an active ingredient or a major active ingredient, and a pharmaceutically acceptable carrier.
[0109] Pharmaceutically acceptable salts constitute a part of this invention. Suitable "pharmaceutically acceptable salts" include conventionally non-toxic salts of the free compounds of this invention, conventionally non-toxic salts of compounds of this invention formed by reactions of inorganic or organic acids, and conventionally non-toxic salts of compounds of this invention formed by reactions of inorganic or organic bases. For example, this includes salts derived from inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, etc., and also salts derived from organic acids such as acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, p-aminobenzenesulfonic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid, ethanedisulfonic acid, oxalic acid, hydroxyethylsulfonic acid, trifluoroacetic acid, etc. As another example, this includes salts derived from inorganic bases such as sodium, potassium, calcium, magnesium, zinc, iron, etc., and also salts derived from organic bases such as ammonia, arginine, lysine, citrulline, histidine, etc. The salts described in this invention include acidic or basic salts formed by the reaction of small amounts of acidic or basic compounds for pharmaceutical purposes. Pharmaceutically acceptable salts are preferably sodium-containing salts.
[0110] One objective of this invention is to research and develop a clinically usable pharmaceutical formulation of a peptide derivative with dual GLP-1R and GIPR targeting agonist activity according to the invention. This formulation may further comprise buffers, preservatives, isotonic agents, solubilizers, tension agents, chelating agents, stabilizers, antioxidants, surfactants, pH adjusters, etc. The concentration is typically from 0.01 mg / ml to 50 mg / ml, and the formulation has a pH of 3.0 to 9.0.
[0111] In one embodiment of the invention, the pharmaceutical preparation is an aqueous preparation, i.e., an aqueous solution, typically a solution, emulsion, or suspension.
[0112] In another embodiment, the pharmaceutical preparation is a lyophilized preparation, which is dissolved in solvent and / or diluent until fully dissolved before use.
[0113] In another embodiment, the pharmaceutical preparation is a ready-to-use dried preparation that does not require pre-dissolution, such as a lyophilized powder for inhalation.
[0114] In another embodiment of the invention, the selection of the pH range of the pharmaceutical formulation is crucial, as it affects the solubility and stability of the peptide derivative with dual targeting agonist effects of GLP-1R and GIPR, and may lead to physical aggregation or adsorption of the peptide under certain specific conditions. In one embodiment of the invention, the pH of the pharmaceutical formulation is 3.0–5.0. In another embodiment of the invention, the pH of the pharmaceutical formulation is 7.0–8.0. In another embodiment of the invention, the pH of the pharmaceutical formulation is 7.5–8.5. In yet another embodiment of the invention, the pH of the pharmaceutical formulation is 5.0–7.5.
[0115] In a further embodiment of the present invention, the buffer is selected from disodium hydrogen phosphate, sodium acetate, etc.; the preservative is selected from phenol, o-cresol, m-cresol, p-cresol, etc.; the isotonic agent is selected from sodium chloride salts, sugars or sugar alcohols, amino acids, propylene glycol, mannitol, etc.; the solubilizer is selected from mannitol, propylene glycol, PEG, glycerol, Tween, ethanol, etc.; the tensioning agent is selected from sodium chloride salts, propylene glycol, glycerol, mannitol, etc.; the chelating agent is selected from EDTA, citrate, etc.; the stabilizer is selected from creatinine, glycine, nicotinamide, PEG, etc.; the antioxidant is selected from sodium bisulfite, sodium sulfite, cysteine, methionine, etc.; the surfactant is selected from polysorbate, glycerol, mannitol, etc.; and the acid-base regulator is selected from hydrochloric acid, phosphoric acid, sulfuric acid, sodium hydroxide, potassium hydroxide, etc.
[0116] Other components may be present in the pharmaceutical formulation of the polypeptide derivative of the present invention, depending on the needs of the pharmaceutical formulation (e.g., long-term stability), including emulsifiers, metal ions, oil carriers, proteins (such as human serum albumin, gelatin or protein, etc.), zwitterions (such as arginine, glycine, lysine, histidine, betaine and taurine, etc.), and other pharmaceutical additives.
[0117] The term "pharmaceutically acceptable carrier" refers to any formulation carrier or medium capable of delivering an effective amount of the active substance of the present invention without interfering with the biological activity of the active substance and without toxic side effects on the host or patient. Representative carriers include water, oil, liposomes, etc.
[0118] For the purposes of drugs or pharmacologically active agents, the term "effective amount" or "therapeutic effective amount" refers to a sufficient amount of a drug or agent that is non-toxic but achieves the desired effect.
[0119] The terms “active ingredient,” “therapeutic agent,” “active substance,” or “active agent” refer to a chemical entity that can effectively treat a target disorder, disease, or symptom.
[0120] "Optional" or "optionally" means that the event or condition described below may occur but is not required to occur, and the description includes both the scenario in which said event or condition occurs and the scenario in which said event or condition does not occur.
[0121] Fourthly, the use of the GLP-1R and GIPR dual-targeting agonist polypeptide derivatives and their pharmaceutically acceptable salts described in this invention in the prevention and / or treatment of diseases, with preferred embodiments, including metabolic syndrome, obesity, diabetes, obesity-related diseases, and diabetes-related diseases. Diabetes includes a group of metabolic diseases characterized by hyperglycemia caused by defects in insulin secretion, insulin action, or both. Based on the pathogenesis, diabetes is classified into type 1 diabetes, type 2 diabetes, and gestational diabetes.
[0122] The GLP-1R and GIPR dual-targeting agonist peptide derivatives of this invention, along with their pharmaceutically acceptable salts, combine the effects of GIP (e.g., on lipid metabolism and weight loss, and blood glucose) with the effects of GLP-1 (e.g., on blood glucose levels and food intake). Therefore, they can be used to accelerate the elimination of excess adipose tissue, resulting in sustained weight loss and improved glycemic control. The dual-targeting agonist effect of GLP-1R and GIPR can also be used to reduce cardiovascular risk factors, such as high cholesterol, including high LDL cholesterol.
[0123] The GLP-1R and GIPR dual-targeting agonist peptide derivatives and their pharmaceutically acceptable salts described in this invention can also be used to treat insulin resistance, impaired glucose tolerance, prediabetes, elevated fasting blood glucose, type 2 diabetes, hypertension, dyslipidemia (or a combination of these metabolic risk factors), atherosclerosis, arteriosclerosis, coronary heart disease, peripheral artery disease, and stroke. These are all conditions that may be associated with obesity. However, the effects of the compounds used in this invention on these conditions can be fully or partially mediated by their effects on body weight, or can be independent of these effects.
[0124] In some embodiments, the GLP-1R and GIPR dual-targeting agonist peptide derivatives of the present invention, along with their pharmaceutically acceptable salts, can play a therapeutic role in obesity-related diseases such as obesity-related inflammation, obesity-related gallbladder disease, and obesity-induced sleep apnea.
[0125] Preferably, it also includes its use in the preparation of medicaments for treating delayed effects of type 2 diabetes and / or preventing the worsening of type 2 diabetes, as well as methods for improving glycemic control in adults with type 2 diabetes, including the use of administering an effective amount of the above-mentioned polypeptide derivative to patients in need as a dietary and exercise supplement.
[0126] The GLP-1R and GIPR dual-targeting agonist peptide derivative and its pharmaceutically acceptable salt described in this invention have positive preventive and therapeutic significance for NASH, which is related to multiple metabolic factors and has a complex pathogenesis. Insulin resistance and lipid metabolism disorders constitute early liver damage, leading to intracellular fat accumulation (NAFLD). As the disease progresses, the body's immune regulation develops, liver cells produce an inflammatory response, which in turn promotes fibrosis, ultimately leading to end-stage liver disease symptoms such as cirrhosis. The GLP-1R and GIPR dual-targeting agonist peptide derivative described in this invention can effectively regulate blood glucose levels and participate in metabolism, and can mediate NASH comprehensively or partially, or independently.
[0127] The metabolic syndrome described in this invention can be diabetes or diabetes-related diseases, or obesity or obesity-related diseases, or NAFLD, NASH, or related diseases. The link between obesity and diabetes is well-known; therefore, these conditions are not independent or mutually exclusive, but may combine. NAFLD, NASH, or related diseases, due to their complex mechanisms, also involve and are related to obesity and diabetes, and may not be independent or mutually exclusive.
[0128] The GLP-1R and GIPR dual-targeting agonist peptide derivatives and their pharmaceutically acceptable salts described in this invention have positive significance for the prevention and treatment of neurodegenerative diseases such as AD (Alzheimer's disease) or PD (Parkinson's disease).
[0129] Fifthly, experimental studies of this invention have revealed that the GLP-1R and GIPR dual-targeting agonist polypeptide derivative of this invention, after conservative or non-conservative amino acid substitution and branching modification in the prior art, unexpectedly exhibits very good in vivo long-term efficacy. Its half-life is significantly better than that of the control drug Tirzepatide, and this is statistically significant. Publicly available data show that the average half-life of the control drug Tirzepatide in human clinical trials is 5.0 days. Based on the pharmacokinetic results of the SD rats in this experiment, the human half-life of the polypeptide derivative (1) can be deduced to be 7.88 days, which means that patients can be given the drug once every half month, greatly facilitating clinical application.
[0130] Sixthly, experimental studies of this invention have found that the GLP-1R and GIPR dual-targeting agonist polypeptide derivatives of this invention can effectively activate GIPR and GLP-1R through conservative or non-conservative amino acid substitution and branching modification in the prior art, achieving dual-target agonist activity and appropriate activity combination and pharmacological effects, similar to the pharmacological effects of the control drug Tirzepatide. Unexpectedly, it was found that some active pharmacological effects were significantly stronger than Tirzepatide and statistically significant, such as the reduction of TC (total cholesterol). Detailed Implementation
[0131] Example 1: Preparation of polypeptide derivatives (1)
[0132]
[0133] MALDI-TOF-MS: [M+H]4800.51
[0134] 1) Synthesis of branched fragments using liquid-phase method;
[0135] Will and The product was coupled by condensation with isobutyl chloroformate under triethylamine conditions, and Boc protection was removed by TFA. Fmoc-Glu-OtBu was coupled with the previous product by condensation with TBTU / DIEA, and Fmoc protection was removed by 20% Pip / NMP solution. The octadecanoic acid with the tBu group monoprotected was coupled to the amino position of Glu in the previous step by condensation. Finally, benzyl ester was removed by hydrogen hydrolysis catalyzed by palladium on carbon to obtain the branched fragment.
[0136]
[0137] 2) Solid-phase synthesis of peptide chains;
[0138] Rink Amide-MBHA resin was selected to sequentially couple Fmoc-protected amino acids onto the solid-phase synthetic resin in reverse order from C-terminus to N-terminus of the peptide chain amino acid sequence of the polypeptide derivative (1). Fmoc was deprotected with 20% Pip / NMP solution and the cycle was repeated until all amino acids of the GLP-1 main chain were completed. Fmoc-Lys(Dde)-OH was selected when condensing Lys of the branched fragment to be joined onto the peptide resin.
[0139] 3) Couple branched fragments to peptide resin;
[0140] The Dde protection was removed using a 2% hydrazine hydrate / ethanolamine solution; the side chain fragment from step 1) was coupled to the peptide resin from step 2) using the condensing agent HATU / DIEA; and the first amino acid Fmoc protection was removed using a 20% Pip / DMF solution.
[0141] 4) Pyrolysis removes protecting groups and resin attachment.
[0142] A lysis buffer was prepared according to a certain ratio (TFA:TIS:H2O:EDT = 96:2:1:1). The fully protected peptide resin was added to the lysis buffer to cleave the target compound from the resin and remove its side chains. TFA was removed by vacuum rotary evaporation, and Et2O was added to the concentrate to precipitate a white solid, which was the crude target product.
[0143] 5) Chromatographic purification
[0144] The purification process involves multiple steps of reversed-phase chromatography or ion chromatography, followed by conversion to a sodium-containing salt solution.
[0145] 6) Freeze-drying
[0146] After freeze-drying, a trifluoroacetic acid polypeptide derivative (1) was obtained as a white or off-white loose solid.
[0147] Example 2: Preparation of polypeptide derivatives (1)
[0148]
[0149] MALDI-TOF-MS: [M+H] 4800.53
[0150] 1) Solid-phase synthesis of peptide chains;
[0151] According to the amino acid sequence of the polypeptide derivative (1), the Fmoc-protected amino acids were sequentially and reverse-coupled to RinkAmide-AM resin. The condensation coupling reagent used was PyBOP / DIEA or DIC / Cl-HOBt. The Fmoc was deprotected with 20% piperidine / DMF solution, and the cycle was repeated until all amino acids were used to complete the polypeptide chain. The Lys of the side chain fragment to be joined was Alloc protected, i.e., Fmoc-Lys(Alloc)-OH. The first amino acid Tyr position was selected as Boc-Tyr(tBu)-OH.
[0152] 2) Solid-phase method to sequentially couple each branched module to peptide resin;
[0153] Tetra(triphenylphosphine)palladium Pd[P(C6H5)3]4 and phenylsilane PhSiH3 / DMF solution were used to deprotect the Lys side chain of the peptide resin with Alloc. 3,6-dioxaoctanoic acid was pre-activated with HATU / DIEA and then coupled to the peptide resin for loading. 3,6-dioxa-1,8-octanediamine with Fmoc monoprotection was added for condensation coupling. Fmoc protection was removed with 20% Pip / DCM. Fmoc-Glu-OtBu was pre-activated with HATU / DIEA and then condensed and coupled. Fmoc protection was removed with 20% Pip / DCM. Eicosanoic acid with tBu monoprotection was condensed and coupled to the α-amino position of Glu to complete the loading and synthesis of the entire branched chain.
[0154] 3) The protecting groups and resin attachment are removed by cleavage to obtain the polypeptide derivative.
[0155] A lysis buffer was prepared according to a certain ratio (TFA:TIS:H2O:phenol = 96:1.5:1.5:1). The fully protected peptide resin was added to the lysis buffer to cleave the target compound from the resin and remove its side chains. TFA was removed by vacuum rotary evaporation, and MTBE was added to the concentrate to precipitate a white solid, which was the crude target product.
[0156] 4) Chromatographic purification
[0157] The solution was purified by multi-step reversed-phase chromatography and finally converted to a salt solution of acetic acid.
[0158] 5) Freeze-drying
[0159] After freeze-drying, an acetic acid polypeptide derivative (1) was obtained as a white or off-white loose solid.
[0160] Referring to Examples 1 and 2 and the synthesis steps described in the patent, some of the other compounds described in the invention were synthesized respectively:
[0161] Peptide derivatives (2) MALDI-TOF-MS: [M+H] 4878.59;
[0162] Peptide derivatives (3) MALDI-TOF-MS: [M+H] 4786.52;
[0163] Peptide derivatives (4) MALDI-TOF-MS: [M+H] 4772.41;
[0164] Peptide derivatives (5) MALDI-TOF-MS: [M+H] 4786.44;
[0165] Peptide derivatives (6) MALDI-TOF-MS: [M+H] 4864.55;
[0166] Peptide derivatives (7) MALDI-TOF-MS: [M+H] 4786.56;
[0167] Peptide derivatives (8) MALDI-TOF-MS: [M+H] 4800.57;
[0168] Peptide derivatives (9) MALDI-TOF-MS: [M+H] 4864.50;
[0169] Polypeptide derivative (10) MALDI-TOF-MS: [M+H]4786.43.
[0170] Example 3 Pharmacokinetic Experiment in SD Rats
[0171] After single subcutaneous administration of polypeptide compound (1) and Tirzepatide to male rats, blood samples were collected at different time points. The concentration of the compound in plasma was determined by LC-MS / MS and relevant pharmacokinetic parameters were calculated to investigate the pharmacokinetic characteristics of the compound in rats.
[0172] Sixteen male SD rats were randomly divided into two groups of eight each, based on their body weight. The rats were fasted for 12–14 hours before administration but allowed free access to water. They were fed 4 hours after administration.
[0173]
[0174] Sample collection. Before and after isoflurane anesthesia, 0.1 ml of blood was collected via the orbital cavity and placed in an EDTAK2 centrifuge tube on ice. The tube was centrifuged at 5000 rpm for 10 min at 4°C, and the plasma was collected.
[0175] Blood collection time points for the SC group: 0, 5, 15, 30 min, 1, 2, 4, 6, 8, 24, 28, 32, 48 h. All plasma samples were stored at -80℃ before analysis and testing.
[0176] The data acquisition and control system software was Analyst 1.5.1 (Applied Biosystems). The sample peak integration method was automatic integration; the ratio of the sample peak area to the internal standard peak area was used as an indicator, and regression was performed with the sample concentration. The regression method was linear regression, with a weighting coefficient of 1 / X. 2 Pharmacokinetic parameters were analyzed using a non-compartmental model with WinNonlin Professional v6.3 (Pharsight, USA). max The measured maximum plasma drug concentration is represented by the area under the plasma drug concentration-time curve (AUC). (0→t) T is calculated using the trapezoidal method. max The time to peak plasma concentration after drug administration. Experimental data are expressed as mean ± standard deviation (Mean ± SD, n ≥ 8) or mean (Mean, n = 8).
[0177] Based on the blood drug concentration data, the pharmacokinetic parameters after drug administration were calculated using the WinNonlin V6.3 non-compartmental model, as shown in the table below.
[0178] Group of polypeptide compounds (1)
[0179]
[0180]
[0181] Example 4: Blood sugar reduction, weight loss, and lipid reduction experiments in ob / ob mice
[0182] Thirty-two ob / ob mice were randomly divided into four groups based on their fasting body weight, fasting serum TC, and LDL: a model control group, a test sample group (1.35 mg / kg), and a positive control group (Tirzepatide, 1.35 mg / kg), with eight mice in each group. Another eight mice were routinely fed as a normal control group (solvent).
[0183] The drug was administered subcutaneously to the back once every 3 days for a total of 8 administrations (D0, D3, D6, D9, D12, D15, D18, D21). The model control group and normal control group were administered the drug at a dose of 0.15 mL / 20 g of physiological saline, while the test sample group and positive control group were administered the drug at a dose of 0.312 mg / kg.
[0184] 1) Weight: Fasting was allowed for 12 hours before grouping, but water intake was permitted. Weight was measured once. Groups were randomly assigned based on weight, TC, and LDL. After grouping, measurements were taken once daily starting from day 0.
[0185] 2) Lee's Index: Body length was measured once before the first administration and once on day 23. Body length is the maximum straight-line length from the tip of the nose to the anus. The mouse was positioned so that its body was stretched out, and the body length was read using a ruler.
[0186] Lee's Index = [weight (g) × 10] 3 Body length (cm) 1 / 3 .
[0187] 3) Measurement of blood glucose (GLU): Measured every 3 days.
[0188] 4) Blood biochemistry (TG, TC, LDL, HDL): Measured once before grouping, and once on D11 and D23.
[0189] 5) Fat-body weight ratio: After euthanasia of mice, subcutaneous fat in the abdomen, perigonadal fat, and subcutaneous fat in the scapula were removed and weighed separately, and the fat-body weight ratio was calculated.
[0190] 6) Food intake and water intake: Measured once a day starting from D0 (except when fasting is required).
[0191] The experimental results are as follows:
[0192] 1) Weight:
[0193] The initial body weight of the polypeptide compound (1) group was lower than that of the model control group (D0, p<0.05), but there was no statistical difference with the Tirzepatide group. Starting from D1, the body weight of animals in both the polypeptide compound (1) and Tirzepatide groups decreased, and the body weight gain during the experiment (D1-D23) was slow and significantly lower than that of the model control group (p<0.01); the average body weight of the polypeptide compound (1) group was slightly higher than that of the Tirzepatide group, but there was no statistical difference.
[0194] Laboratory animal weight record sheet
[0195]
[0196]
[0197] Compared with the model control group, *p<0.05, **p<0.01; compared with the corresponding positive control group, #p<0.05, ##p<0.01.
[0198] 2) Lee's Index
[0199] Lee's index is an effective indicator of obesity in rats. All animals showed an increase in Lee's index, with the smallest increase observed in the normal control group. Compared to the model control group, the Lee's index was slightly lower in each drug-treated group. These results indicate that both the test drug and the positive control drug inhibited obesity in ob / ob mice, and the control efficacy of the test drug and the positive control drug was similar, with no statistically significant difference.
[0200] Animal Lee's Index Table
[0201]
[0202] 3) Random blood glucose:
[0203] The animals underwent their first blood glucose test on the third day after administration. The results showed that the blood glucose concentration in each administration group was significantly lower than that in the normal group, and the blood glucose concentration was well controlled during D0-D10. During the experiment, the blood glucose concentration of the animals gradually increased, which may be related to their age and weight gain. Compared with the model control group, the blood glucose values of the normal control group animals on D14-D23 were significantly lower than those of the model control group mice, indicating that the basal blood glucose value of ob / ob mice was higher. Compared with the model control group mice, both the test drug and the positive control drug had significant hypoglycemic effects to varying degrees on D3-D23. There was no significant difference between the administration group and the positive control drug (peptide compound (1) / Tirzepatide).
[0204] Table of Blood Glucose Changes in Experimental Animals
[0205]
[0206]
[0207] Compared with the model control group, *p<0.05, **p<0.01; compared with the corresponding positive control group, #p<0.05, ##p<0.01.
[0208] 4) Blood biochemistry
[0209] (1) TC: Before the experiment (D0), the initial TC values of peptide compound (1) and the model group were higher than those of other mouse groups of the same strain. Compared with different time points after self-administration, the TC levels of obese mice in the peptide compound (1) and Tirzepatide groups were significantly reduced after administration, indicating that the test drug and the positive control drug can significantly reduce TC levels. The results of D11 and D23 show that the ability of peptide compound (1) to reduce TC is similar to that of Tirzepatide. Moreover, the peptide compound (1) group had a stronger ability to reduce TC when the initial value was higher, and it approached the level of the Tirzepatide group at D23, and the statistical significance improved significantly from ##p<0.01 to #p<0.05.
[0210] (2) TG: Before the experiment (D0), the initial values of peptide compound (1) and Tirzepatide were lower than those of other mouse groups of the same strain. Compared with different time points after self-administration, the TG of obese mice in the peptide compound (1) and Tirzepatide groups decreased significantly after administration, indicating that the test drug and the positive control drug can significantly reduce TG content. At D23, the ability of peptide compound (1) to reduce TG was slightly weaker than that of Tirzepatide (peptide compound (1) vs Tirzepatide, p<0.01).
[0211] (3) LDL: Before the start of the experiment (D0), the initial values of peptide compound (1) and Tirzepatide were higher than those of other mouse groups of the same strain. Compared with different time points after self-administration, at D11 and D23 after administration, the LDL levels of obese mice in the peptide compound (1) and Tirzepatide groups were significantly lower and significantly lower than those in the model control group (p<0.01). There was no statistically significant difference between the peptide compound (1) and Tirzepatide groups.
[0212] (4) HDL: During the experiment, the HDL levels of mice in the model control group were higher than those in the normal control group. Before administration (D0), the HDL levels of mice of the same strain were relatively similar. Compared with the model control group, the HDL levels of both the test group and the positive control group were significantly reduced on D11 and D23 after administration.
[0213] The above results indicate that both the test drug and the positive control drug can reduce the concentrations of TG, TC, LDL and HDL in animals.
[0214] Table of Changes in TC Content in Animal Blood
[0215]
[0216] Compared with the model control group, *p<0.05, **p<0.01; compared with the corresponding positive control group, #p<0.05, ##p<0.01.
[0217] Animal blood TG content table
[0218]
[0219] Compared with the model control group, *p<0.05, **p<0.01; compared with the corresponding positive control group, #p<0.05, ##p<0.01.
[0220] Animal blood LDL content table
[0221]
[0222] Compared with the model control group, *p<0.05, **p<0.01; compared with the corresponding positive control group, #p<0.05, ##p<0.01.
[0223] Animal blood HDL content table
[0224]
[0225] Compared with the model control group, *p<0.05, **p<0.01; compared with the corresponding positive control group, #p<0.05, ##p<0.01.
[0226] 5) Fat-to-body weight ratio
[0227] Twenty-three days after administration, the mice were dissected, and fat was separated from different sites. The fat-to-body weight ratio was calculated using the formula (fat / body weight × 100). The results showed that the fat-to-body weight ratio of the model control group mice was significantly higher than that of the normal control group mice in all sites. The polypeptide compound (1) significantly reduced subcutaneous fat in the abdomen and around the gonads of ob / ob mice, and the effect was not significantly different from that of the positive control drug Tirzepatide. In addition, the drug had no effect on the subcutaneous fat-to-body weight ratio of the scapula.
[0228] Fat-to-body weight ratio table
[0229]
[0230]
[0231] Compared with the model control group, *p<0.05, **p<0.01; compared with the corresponding positive control group, #p<0.05, ##p<0.01.
[0232] 6) Food intake and water intake
[0233] After drug administration, the animals' food intake decreased significantly. The overall feeding trend of the animals showed a certain correlation with the frequency of drug administration, with the lowest food intake on the day of administration, followed by a slow increase over time, but the overall increase was lower than that of the model control group and the normal control group. In the later stages of the experiment, the overall food intake of the animals increased, which may be related to the increase in age and weight. The experimental results indicate that both the test drug and the positive control drug have significant feeding control effects.
[0234] There were significant differences in water intake among the experimental animals in each group, with the drug-treated group showing lower intake than the normal group and the model control group. A noticeable decrease in water intake was observed after drug administration, with the most pronounced effect after the first administration. On day 11, water intake significantly increased in all groups, possibly related to subsequent fasting, but the increase was observed in all groups of mice. The experimental results indicate that both the test drug and the positive control drug have significant water intake control effects.
Claims
1. A polypeptide derivative as shown in (I) or a pharmaceutically acceptable salt thereof, wherein Xaa in the main chain 20 It is Lys and its side chain ε-amino is connected to the branch chain X1 in formula (II) in the form of an amide bond; Tyr-Aib-Asp-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Xaa2 0-Glu-Phe-Val-Gln-Trp-Leu-Leu-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 (Ⅰ) in, Aib is aminoisobutyric acid, which is linked to the preceding and following amino acids by amide bonds. Additionally, in equation (II), n is 18; X2 is... Meanwhile, X1 is .
2. The polypeptide derivative of claim 1 or a pharmaceutically acceptable salt thereof, wherein the amino acid is L-type and the pharmaceutically acceptable salt is a sodium-containing salt.
3. The method for preparing the polypeptide derivative or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 2, characterized in that, It includes steps such as branched fragment synthesis, fully protected polypeptide backbone synthesis, branched chain coupling to peptide resin, cleavage to remove peptide chain and side chain full protection, chromatographic purification and lyophilization, or solid-phase synthesis of peptide chain, solid-phase coupling of each branched module to peptide resin, cleavage to remove protecting groups and resin loading, chromatographic purification and lyophilization.
4. A pharmaceutical composition comprising any one of the polypeptide derivatives of claims 1 to 2 or a pharmaceutically acceptable salt thereof, said pharmaceutical composition further comprising a pharmaceutically acceptable carrier.
5. The use of the polypeptide derivative of any one of claims 1 to 2 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 4, in the preparation of a medicament for the treatment and / or prevention of at least one of the following diseases: metabolic syndrome, obesity, diabetes, obesity-related diseases, and diabetes-related diseases.
6. The use of the polypeptide derivative of any one of claims 1 to 2 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 4, in the preparation of a medicament for the treatment and / or prevention of at least one of the following diseases: insulin resistance, impaired glucose tolerance, prediabetes, elevated fasting blood glucose, type II diabetes, hypertension, dyslipidemia, atherosclerosis, arteriosclerosis, coronary heart disease, peripheral artery disease, and stroke.
7. The use of the polypeptide derivative of any one of claims 1 to 2 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 4, in the preparation of a medicament for the treatment and / or prevention of at least one of the following diseases: obesity-related inflammation, obesity-related gallbladder disease, and obesity-induced sleep apnea.
8. The use of the polypeptide derivative of any one of claims 1 to 2 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 4, in the preparation of a medicament for reducing food intake, reducing β-cell apoptosis, increasing pancreatic β-cell function, increasing β-cell clusters and / or restoring glucose sensitivity to β-cells.
9. The use of the polypeptide derivative of any one of claims 1 to 2 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 4, in the preparation of a medicament for the treatment and / or prevention of at least one of the following diseases: non-alcoholic simple fatty liver, non-alcoholic steatohepatitis and its associated cirrhosis and hepatocellular carcinoma.
10. The use of the polypeptide derivative of any one of claims 1 to 2 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 4, in the preparation of a medicament for the treatment and / or prevention of at least one of the following diseases: neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.
Citation Information
Patent Citations
Peptide compound
CN105209485A
GIP-GLP-1 dual agonist compounds and methods
CN105849122A
Gip-glp-1 dual agonist compounds and methods
CN104470948A
GIP and GLP-1 co-agonist compounds
CN107207576A
